EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Genetic polymorphism and pharmacokinetics/toxicokinetics of carbamazepine: A general review

Aleksandra Kovacevic, Vladan Lukic, Bojana Cikota-Aleksic, Slobodan Jankovic, Viktorija Dragojevic-Simic

Vojnosanitetski pregled · 2026 · 83 (3) · 143-152

DOI: 10.2298/vsp251124013k ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vojnosanitetski pregled, 2026. Verfasst von Aleksandra Kovacevic und 4 weiteren Autor:innen. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbamazepine (CBZ) is a widely used medication in treating epilepsy, bipolar disorder, and neuropathic pain. Its pharmacokinetic profile is highly variable due to slow absorption, extensive metabolism, and auto-induction. Genetic polymorphisms affect transporters and metabolic enzymes, additionally modifying therapeutic response, and lead to nonlinear and unpredictable toxicokinetics in overdose. CBZ is primarily metabolized by cytochrome P450 (CYP) enzymes CYP3A4, CYP3A5, and CYP2C8 to the active metabolite CBZ-10, 11-epoxide (CBZ-E), with subsequent hydrolysis by epoxide hydrolase 1 (EPHX1) and glucuronidation by uridine diphosphate glucuronosyltransferase 2B7 (UGT2B7), with other CYPs additionally contributing to the formation of reactive intermediates and inactive CBZ metabolites. Polymorphisms in genes encoding enzymes (EPHX1, CYP3A4/5, and UGT2B7) and transporters (ABCB1, ABCC2, RALBP1) can affect CBZ and CBZ-E exposure, maintenance dose, and the risk of adverse drug reactions. In overdose cases, CBZ exhibits saturable epoxidation, which leads to the accumulation of the drug and its active metabolite, prolonged elimination, and neurotoxicity, while serum concentrations correlate poorly with clinical findings. Therapeutic monitoring of the drug and its active metabolite in patients’ blood, together with pharmacogenetic testing, could improve both the individualization of therapy and the management of overdose.

Zitieren

APA

Kovacevic, A., Lukic, V., Cikota-Aleksic, B., Jankovic, S., & Dragojevic-Simic, V. (2026). Genetic polymorphism and pharmacokinetics/toxicokinetics of carbamazepine: A general review. Vojnosanitetski pregled, 83(3), 143-152. https://doi.org/10.2298/vsp251124013k

Vancouver

Kovacevic A, Lukic V, Cikota-Aleksic B, Jankovic S, Dragojevic-Simic V. Genetic polymorphism and pharmacokinetics/toxicokinetics of carbamazepine: A general review. Vojnosanitetski pregled. 2026;83(3):143-152. doi:10.2298/vsp251124013k

BibTeX
@article{Kovacevic2026,
  author = {Kovacevic, Aleksandra and Lukic, Vladan and Cikota-Aleksic, Bojana and Jankovic, Slobodan and Dragojevic-Simic, Viktorija},
  title = {Genetic polymorphism and pharmacokinetics/toxicokinetics of carbamazepine: A general review},
  journal = {Vojnosanitetski pregled},
  year = {2026},
  volume = {83},
  number = {3},
  pages = {143--152},
  doi = {10.2298/vsp251124013k}
}
Kostenlos starten →